Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia
Fiche publication
Date publication
décembre 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel
Tous les auteurs :
Belleville I, Chague F, Petit JM, Boujon B
Lien Pubmed
Résumé
Used in its neurological indication, cabergoline is known to induce cardiac valve regurgitations, essentially mitral and aortic valvular diseases, by its action on the 5HT2b receptors. Until now, it was assumed that the dose and the duration of exposure were the major factors of appearance. We describe a case of aortic insufficiency which developed in a patient given low doses of cabergoline (0.5 mg weekly) for non-tumoral hyperprolactinemia. Because of previous use of appetite suppressants and of bromocriptine, the exclusive responsibility of cabergoline remained uncertain. The potential gravity of these valvular heart diseases emphasizes the importance of careful cardiologic examination before and during treatment. (c) 2007 Elsevier Masson SAS. Tous droits reserves.
Référence
Ann Endocrinol (Paris). 2007 Dec;68(6):464-6